X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The joint venture collaboration comprises 13 brands across 6 therapeutic areas primarily focused on pain management, including Abstral (fentanyl) and PecFent for breakthrough cancer pain, Moventig for opioid-induced constipation, and Adcal-D3® for osteoporosis.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Abstral
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Grunenthal Meds
Deal Size: $83.2 million Upfront Cash: Undisclosed
Deal Type: Collaboration August 02, 2023
Details:
The collaboration leads to the successful reformulation of an investigational, orally dosed small molecule in Grünenthal’s pipeline to improve its bioavailability. Phase 1 studies of the molecule will be supported by using the Catalent Xpress Pharmaceutics™ platform.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Catalent Pharma Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 15, 2023
Details:
Key products in the portfolio include Abstral® and PecFent® (Fentanyl) for breakthrough cancer pain, Moventig® (Naloxegol) for opioid-induced constipation and Adcal-D3® (calcium and vitamin D3) for osteoporosis.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Abstral
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Kyowa Kirin
Deal Size: Undisclosed Upfront Cash: $82.7 million
Deal Type: Collaboration November 24, 2022
Details:
Nebido (having testosterone undecanoate) is the only available injectable long-acting depot preparation of testosterone undecanoate, developed for the treatment of male hypogonadism.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Nebido
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Bayer AG
Deal Size: $498.1 million Upfront Cash: Undisclosed
Deal Type: Acquisition November 02, 2022
Details:
RTX is an intra-articular injection of resiniferatoxin developed for the treatment of pain in patients with moderate to severe pain associated with knee osteoarthritis.
Lead Product(s): Resiniferatoxin
Therapeutic Area: Rheumatology Product Name: RTX
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
The agreement includes competitive investment commitments for launch and commercialisation. Manufacturing and supply of RTX (resiniferatoxin) to Shionogi will be carried out exclusively by Grünenthal.
Lead Product(s): Resiniferatoxin
Therapeutic Area: Rheumatology Product Name: RTX
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Shionogi
Deal Size: $670.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 04, 2022
Details:
Nebido (testosterone undecanoate) is used for male hypogonadism. It is used for treating clinical symptoms such as regression of secondary sexual characteristics, change in body composition, asthenia, reduced libido or erectile dysfunction due to low testosterone levels.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Nebido
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Bayer AG
Deal Size: $506.6 million Upfront Cash: Undisclosed
Deal Type: Acquisition July 14, 2022
Details:
A key objective of MPC-06-ID (rexlemestrocel-L) is to demonstrate reduction in pain and opioid usage and and position rexlemestrocel-L as a potential opioid-sparing agent.
Lead Product(s): Rexlemestrocel-L,Hyaluronic Acid
Therapeutic Area: Neurology Product Name: MPC-06-ID
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Recipient: Mesoblast
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Details:
The Phase III study investigates the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) to support an extension of the U.S. label.
Lead Product(s): Capsaicin
Therapeutic Area: Neurology Product Name: Qutenza
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2021
Details:
Phase III studies investigating efficacy, safety and tolerability of Qutenza (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) and the efficacy, safety and tolerability of Resiniferatoxin in patients with pain associated with osteoarthritis of the knee.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
